BHC
REGN icon

Bowen Hanes & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

Bowen Hanes & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-415
Closed -$263K – 154
2025
Q1 		$263K Sell
415
-50
-11% -$34.4K 0.01% 142
2024
Q4 		$331K Sell
465
-35,985
-99% -$30.2M 0.01% 138
2024
Q3 		$38.3M Buy
36,450
+1,660
+5% +$1.85M 1.01% 48
2024
Q2 		$36.6M Buy
34,790
+4,150
+14% +$4.02M 1.01% 44
2024
Q1 		$29.5M Buy
+30,640
New +$29.1M 0.84% 49

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bowen Hanes & Co's REGN Position: Q2 2025 in Review

Bowen Hanes & Co sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 415 shares — an estimated $263K sold.

Bowen Hanes & Co first reported a position in REGN in Q1 2024 and held it in 5 quarters. The position peaked at $38.3M in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Bowen Hanes & Co reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bowen Hanes & Co sold 415 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $263K.
  • Bowen Hanes & Co first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Bowen Hanes & Co's Regeneron Pharmaceuticals position peaked at $38.3M in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Bowen Hanes & Co's 13F filing for Q2 2025, filed 12 Aug 2025.